Elaine M. Jagoda, M.S.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 1B55
- Bethesda, MD 20892-1088
- 240-858-3068
- 240-541-4527
- ejagoda@mail.nih.gov
RESEARCH SUMMARY
Elaine Jagoda serves as the lead for the Laboratory of Radiopharmaceutical Development in the Molecular Imaging Branch of the National Cancer Institute. She has over 20 years of research experience in the development of PET/SPECT imaging agents in academic (George Washington University, Washington, DC), pharmaceutical (Bristol-Myers Squibb, Princeton, NJ; Merck Research Laboratories, West Point, PA), and government (PET Dept, Clinical Center; NIBIB, Bethesda, MD) settings. Her research is focused on pre-clinical development of novel PET molecular imaging agents for cancer which would work hand in hand with new targeted therapies proving useful not only for patient diagnosis and selection but in monitoring patient responses as well.
Areas of Expertise
1) PET/SPECT imaging 2) molecular imaging 3) radiopharmaceutical development 4) radioligand assay development
Elaine M. Jagoda, M.S.
Publications
Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab
[76Br]BMK-152, a Nonpeptide Analogue, With High Affinity and Low Nonspecific Binding for the Corticotropin-Releasing Factor Type 1 Receptor
Regional brain uptake of the muscarinic ligand, [18F]FP-TZTP is greatly decreased in M2 receptor knockout mice but not in M1, M2, M3, and M4 receptor knockout mice
Immuno-PET of the Tumor Endothelial Marker 8
Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) Labeled Peptide
Biography
Elaine M. Jagoda, M.S.
Elaine Jagoda serves as the lead for the Laboratory of Radiopharmaceutical Development in the Molecular Imaging Branch of the National Cancer Institute. Ms. Jagoda has over 20 years of research experience in the development of PET/SPECT imaging agents in academic (George Washington University, Washington, DC), pharmaceutical (Bristol-Myers Squibb, Princeton, NJ; Merck Research Laboratories, West Point, PA), and government (PET Dept, Clinical Center; NIBIB, Bethesda, MD) settings. Her research is focused on pre-clinical development of novel PET molecular imaging agents for cancer which would work hand in hand with new targeted therapies proving useful not only for patient diagnosis and selection but in monitoring patient responses as well.
